Auger radiation targeted into DNA: A therapy perspective

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 11, 2006, Pages 1352-1363

  Buchegger, Franz ^a   Perillo Adamer, Florence ^a   Dupertuis, Yves M ^b   Bischof Delaloye, Angelika ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Auger radiation; Dosimetry; Nuclear targeting; Treatment

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; GROWTH FACTOR; HORMONE; IBRITUMOMAB TIUXETAN; IDOXURIDINE; IODINE 123; IODINE 125; OLIGONUCLEOTIDE; PEPTIDE; RADIOISOTOPE; RITUXIMAB; THALLIUM 201; TOSITUMOMAB; TRASTUZUMAB;

ALPHA RADIATION; AUGER ELECTRON SPECTROSCOPY; BYSTANDER EFFECT; CELL NUCLEUS; CYTOPLASM; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; GENE TARGETING; HUMAN; HYPERTHYROIDISM; LINEAR ENERGY TRANSFER; LYMPHOMA; NONHUMAN; RADIATION DOSE; RADIATION PROTECTION; RADIOIMMUNOTHERAPY; REVIEW; THYROID CANCER; TUMOR CELL;

DNA DAMAGE; DNA, NEOPLASM; ELECTRONS; HUMANS; NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 33750366059     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0187-2     Document Type: Review

References (119)

1. Larson SM, Krenning EP. A pragmatic perspective on molecular targeted radionuclide therapy. J Nucl Med 2005;46 Suppl 1:1S-3S
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306
3. Feinendegen LE. Contributions of nuclear medicine to the therapy of malignant tumors. J Cancer Res Clin Oncol 1993;119:320-322
4. Boelaert K, Franklyn JA. Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers? Lancet 2003;361:796-797
5. Berlin NI, Wasserman LR. Polycythemia vera: a retrospective and reprise. J Lab Clin Med 1997;130:365-373
6. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6:392-400
7. Liepe K, Runge R, Kotzerke J. Systemic radionuclide therapy in pain palliation. Am J Hosp Palliat Care 2005;22:457-464
8. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis - a systemic review. Radiother Oncol 2005;75:258-270
9. Mach JP, Carrel S, Merenda C, Sordat B, Cerottini JC. In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature 1974;248:704-706
10. Primus FJ, Wang RH, Goldenberg DM, Hansen HJ. Localization of human GW-39 tumors in hamsters by radiolabeled hetero-specific antibody to carcinoembryonic antigen. Cancer Res 1973;33:2977-2982
11. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52:281-296
12. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507-1529
13. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792-795
14. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-418
15. Couturier O, Supiot S, Graef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 2005;32:601-614
16. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med 2005;46 Suppl 1:199S-204S
17. Thames HD, Hendry JH. Fractionation in radiotherapy. 1st edn. London: Taylor and Francis, 1987
18. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002;94:1332-1348
19. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005;46:4S-12S
20. Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003;22:5792-5812
21. Vilenchik MM, Knudson AG. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci USA 2003;100:12871-12876
22. De Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003;30:463-469
23. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565-7573
24. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubitschek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase I/II study. Blood 2004;103:4429-4431
25. Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol 2000;27:62-73
26. Faderl S, Coutre S, Byrd JC, Dearden C, Denes A, Dyer MJ, et al. The evolving role of alemtuzumab in management of patients with CLL. Leukemia 2005;19:2147-2152
27. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833
28. Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol 2006;17:381-390
29. Trümper L. Radioimmuntherapie in der Hämatologie und Onkologie. 1st edn. Bremen: Uni-Med Science, 2005
30. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902-1909
31. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res 1997;57:447-453
32. Sharkey RM, Weadock KS, Natale A, Haywood L, Aninipot R, Blumenthal RD, et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 1991;83:627-632
33. Hindorf C, Emfietzoglou D, Linden O, Kostarelos K, Strand SE. Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma. Cancer Biother Radiopharm 2005;20:224-230
34. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S-17S
35. Auger P. Sur les rayons beta secondaires produits dans un gaz par des rayons X. Comp Rend 1925;180:65-68
36. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol 1996;41:1973-1992
37. Sastry KS. Biological effects of the Auger emitter iodine-125: a review. Report No. 1 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1992;19:1361-1370
38. Howell RW. Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1992;19:1371-1383
39. Humm JL, Howell RW, Rao DV. Dosimetry of Auger-electrone-mitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1994;21:1901-1915
40. 125I in mammalian cells. Radiat Res 1987;111:305-318
41. Howell RW, Narra VR, Sastry KS, Rao DV. On the equivalent dose for Auger electron emitters. Radiat Res 1993;134:71-78
42. Lobachevsky PN, Martin RF. Iodine-125 decay in a synthetic oligodeoxynucleotide. I. Fragment size distribution and evaluation of breakage probability. Radiat Res 2000;153:263-270
43. Lobachevsky PN, Karagiannis TC, Martin RF. Plasmid DNA breakage by decay of DNA-associated Auger electron emitters: approaches to analysis of experimental data. Radiat Res 2004;162:84-95
44. Panyutin IG, Neumann RD. The potential for gene-targeted radiation therapy of cancers. Trends Biotechnol 2005;23:492-496
45. Bishayee A, Rao DV, Howell RW. Radiation protection by cysteamine against the lethal effects of intracellularly localized Auger electron, alpha- and beta-particle emitting radionuclides. Acta Oncol 2000;39:713-720
46. Bishayee A, Hill HZ, Stein D, Rao DV, Howell RW. Free radical-initiated and gap junction-mediated bystander effect due to nonuniform distribution of incorporated radioactivity in a three-dimensional tissue culture model. Radiat Res 2001;155:335-344
47. 125I]iodo-2′- deoxyuridine. Radiat Res 1989;118:532-544
48. 125I compared with that of densely ionising alpha-particles. Lancet 1989;2:650-653
49. 125I and the problem of quality factor. Radiat Environ Biophys 1987;26:181-188
50. Howell RW, Rao DV, Hou DY, Narra VR, Sastry KS. The question of relative biological effectiveness and quality factor for Auger emitters incorporated into proliferating mammalian cells. Radiat Res 1991;128:282-292
51. Narra VR, Howell RW, Harapanhalli RS, Sastry KS, Rao DV. Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design. J Nucl Med 1992;33:2196-2201
52. Hoyes KP, Nettleton JS, Lawson RS, Morris ID. Transferrin-dependent uptake and dosimetry of Auger-emitting diagnostic radionuclides in human spermatozoa. J Nucl Med 1998;39:895-899
53. Hoyes KP, Morris ID, Hendry JH, Sharma HL. Transferrin-mediated uptake of radionuclides by the testis. J Nucl Med 1996;37:336-340
54. 114mIn in adult and neonatal rats. Reprod Toxicol 1995;9:297-305
55. Hoyes KP, Lord BI, McCann C, Hendry JH, Morris ID. Transgenerational effects of preconception paternal contamination with (55)Fe. Radiat Res 2001;156:488-494
56. 124I] iododeoxyuridine. Cancer Res 2000;60:624-635
57. Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA 2002;99:13765-13770
58. Sgouros G. Dosimetry of internal emitters. J Nucl Med 2005;46 Suppl 1:18S-27S
59. Stabin MG, Howell RW, Colas-Linhart NC. Modeling radiation dose and effects from internal emitters in nuclear medicine: from the whole body to individual cells. Cell Mol Biol (Noisy-legrand) 2001;47:535-543
60. Goddu SM, Howell RW, Rao DV. Calculation of equivalent dose for Auger electron emitting radionuclides distributed in human organs. Acta Oncol 1996;35:909-916
61. 123I]iododeoxyuridine. Eur J Nucl Med Mol Imaging 2003;30:239-246
62. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987;109:78-89
63. Di Croce L, Okret S, Kersten S, Gustafsson JA, Parker M, Wahli W, et al. Steroid and nuclear receptors. Villefranche-sur-Mer, France, May 25-27, 1999. EMBO J 1999;18:6201-6210
64. Beato M, Truss M, Chavez S. Control of transcription by steroid hormones. Ann N Y Acad Sci 1996;784:93-123
65. 125I- oestrogen decay in non-oestrogen receptor-expressing human breast cancer cells, MDA-231 and oestrogen receptor-expressing MCF-7 cells. Int J Radiat Biol 2001;77:955-962
66. 125I-estrogen decays in estrogen receptor-expressing MCF-7 human breast cancer cells. Radiat Res 2001;155:328-334
67. DeSombre ER, Hughes A, Hanson RN, Kearney T. Therapy of estrogen receptor-positive micrometastases in the peritoneal cavity with Auger electron-emitting estrogens - theoretical and practical considerations. Acta Oncol 2000;39:659-666
68. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000;41:429-438
69. 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 2003;44:1469-1478
70. 1-octreotide. J Nucl Med 1996;37:2002-2006
71. Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using Auger electron emitters. J Nucl Med 2005;46:2097-2103
72. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2005;32:1288-1295
73. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S-66S
74. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-140
75. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004;1014:234-245
76. 125I] iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors. Eur J Cancer 1996;32A:1603-1608
77. 125I]iodo-2′-deoxyuridine in mammalian cells following treatment with 5-fluoro-2′-deoxyuridine. J Nucl Biol Med 1991;35:167-173
78. Lawrence TS, Davis MA, McKeever PE, Maybaum J, Stetson PL, Normolle DP, et al. Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo. Cancer Res 1991;51:3900-3905
79. Dupertuis YM, Vazquez M, Mach JP, de Tribolet N, Pichard C, Slosman DO, et al. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res 2001;61:7971-7977
80. 125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts. Int J Cancer 2004;110:145-149
81. 125I-iododeoxyuridine. Eur J Nucl Med Mol Imaging 2006;33:613-620
82. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-456
83. Wilson WL, Bisel HF, Krementz ET, Lien RC, Prohaska JV. Further clinical evaluation of 2′-deoxy-5-fluorouridine (NSC-27640). Cancer Chemother Rep 1967;51:85-90
84. Serlin O, Wolkoff JS, Amadeo JM, Keehn RJ. Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 1969;24:223-228
85. Pressacco J, Mitrovski B, Erlichman C, Hedley DW. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 1995;55:1505-1508
86. Valdes R, Casado FJ, Pastor-Anglada M. Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. Biochem Biophys Res Commun 2002;296:575-579
87. 125I-triplex-forming oligonucleotides in cells. Int J Radiat Biol 2004;80:927-931
88. Panyutin IG, Winters TA, Feinendegen LE, Neumann RD. Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for anti-gene radiotherapy. Q J Nucl Med 2000;44:256-267
89. Cammilleri S, Sangrajrang S, Perdereau B, Brixy F, Calvo F, Bazin H. Biodistribution of iodine-125 tyramine transforming growth factor alpha antisense oligonucleotide in athymic mice with a human mammary tumour xenograft following intratumoral injection. Eur J Nucl Med 1996;23:448-452
90. 111In-labeled peptide nucleic acids. Eur J Nucl Med Mol Imaging 2004;31:837-845
91. Lee JF, Stovall GM, Ellington AD. Aptamer therapeutics advance. Curr Opin Chem Biol 2006;10:282-289
92. Lee JH, Canny MD, De EA, Krilleke D, Ng YS, Shima DT, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA 2005;102:18902-18907
93. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315-6320
94. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, et al. Tumor targeting by an aptamer. J Nucl Med 2006;47:668-678
95. Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F. Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 1991;253:314-317
96. Klussmann S, Nolte A, Bald R, Erdmann VA, Furste JP. Mirror-image RNA that binds D-adenosine. Nat Biotechnol 1996;14:1112-1115
97. Kim SJ, Kim MY, Lee JH, You JC, Jeong S. Selection and stabilization of the RNA aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem Biophys Res Commun 2002;291:925-931
98. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996;14:1787-1797
99. Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. J Nucl Med 2000;41:2089-2097
100. Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. Clin Cancer Res 2005;11:777-786
101. 111In-labeled antibodies to HER-2. Mol Cancer Ther 2005;4:927-937
102. Michel RB, Brechbiel MW, Mattes MJ. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. J Nucl Med 2003;44:632-640
103. Hosono M, Hosono MN, Kraeber-Bodere F, Devys A, Thedrez P, Fiche M, et al. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. J Nucl Med 1998;39:1608-1613
104. Sisson JC. Radiopharmaceuticals for nuclear endocrinology at the University of Michigan. Cancer Biother Radiopharm 2000;15:305-318
105. Sisson JC, Shapiro B, Hutchinson RJ, Shulkin BL, Zempel S. Survival of patients with neuroblastoma treated with 125-I MIBG. Am J Clin Oncol 1996;19:144-148
106. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 2001;40:602-608
107. 125I on the DNA of the rat thyroid. I. Comparative study with emphasis on the postradiation hypothyroidism occurrence. Radiat Res 1983;93:525-533
108. 125J of Basedow's disease. Indications and results relative to the incidence of post-actinic hypothyroidism [in Italian]. Minerva Med 1979;70:135-141
109. McDougall IR, Greig WR, Gillespie FC. Iodine-125 therapy for thyrotoxicosis: background and evaluation in 148 patients. Strahlentherapie [Sonderb] 1972;72:243-252
110. McDougall IR, Greig WR, Gray HW, Gillespie FC. Iodine-125 treatment for thyrotoxicosis. Lancet 1970;2:840-842
111. Gillespie FC, Orr JS, Greig WR. Microscopic dose distribution from 125-I in the toxic thyroid gland and its relation to therapy. Br J Radiol 1970;43:40-47
112. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005;11:1483-1489
113. Buchsbaum DJ, Chaudhuri TR, Zinn KR. Radiotargeted gene therapy. J Nucl Med 2005;46 Suppl 1:179S-186S
114. 111In-DTPA]octreotide. J Nucl Med 2004;45:1168-1171
115. 123I]iodo- 2′-deoxyuridine in a patient with a brain tumor. J Nucl Med 1996;37:19S-22S
116. 123I]iodo- 2′- deoxyuridine in patients with liver metastases from colorectal cancer. J Nucl Med 1996;37:22S-25S
117. 123I]iodo-2′ deoxyuridine in patients with liver metastases from colorectal cancer. Acta Oncol 1996;35:941-945
118. Bodei L, Kassis AI, Adelstein SJ, Mariani G. Radionuclide therapy with iodine-125 and other Auger-electron-emitting radionuclides: experimental models and clinical applications. Cancer Biother Radiopharm 2003;18:861-877
119. 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm 2005;20:16-26